Cryofocus Medtech Gets China Nod for Cryoablation System

MT NewswiresMar 7 14:04

Kangfeng Biotechnology-B (06922.HK): The malignant stenosis cryoablation system has obtained approval from the National Medical Products Administration.

On March 6, Gelonghui reported that Kangfeng Bio-B (06922.HK) announced that on March 6, 2025, the group's malignant stenosis cryoablation system, one of the group's respiratory intervention products, composed of cryotherapy equipment and airway cryoablation catheters, has obtained the approval granted by the National Medical Products Administration. The malignant stenosis cryoablation system is a self-developed cryoablation system designed to ablate malignant airway tumor tissues and reduce the frequency of airway restenosis. During the surgical process, the malignant stenosis cryoablation system utilizes the ultra-low temperature generated by the cryoablation system to ablate tumor cells in the tracheal lumen and its wall, and then proceeds with rewarming.

Gelonghui FinanceMar 6 22:13

Kangfeng Biological - B [06922] is currently reported at 6.64 Hong Kong dollars, with a decline of 13.20%.

As of 15:07, Kangfeng Biotech - B [06922] is priced at 6.64 HKD, down 1.01 HKD or 13.20% from yesterday's closing price of 7.65 HKD, with a transaction value of 0.0804 million HKD. Today's highest price is 7.69 HKD, and the lowest price is 6.97 HKD. Based on yesterday's closing price, the 10-day average price is 7.88 HKD, the 50-day average price is 7.26 HKD, the current PE is -17.02 times, and the 14-day strength index is 30.53.

Jinwu Financial NewsJan 22 15:07

Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space

Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.

Zhitong FinanceOct 17, 2024 14:04

Cryofocus Medtech's Subsidiary to Collaborate on Research, Development of Cryoballoon Ablation for Lung Cancer

MT NewswiresOct 16, 2024 20:06

Kangrun Biotech-B (06922.HK): Signed a research cooperation agreement with the Guangzhou National Laboratory and the First Affiliated Hospital of Guangzhou Medical University.

Gelonghui, October 16th - Kangrun Biotech-B (06922.HK) announced that its wholly owned subsidiary, Ningbo Shengjie Kang Biotechnology Co., Ltd. ("Ningbo Shengjie Kang"), will participate in and manage a research project approved by the Guangzhou National Laboratory in collaboration with the First Affiliated Hospital of Guangzhou Medical University. Ningbo Shengjie Kang, the Guangzhou National Laboratory, and the First Affiliated Hospital of Guangzhou Medical University recently signed a research cooperation agreement ("Research Cooperation Agreement") regarding the above-mentioned project. The Guangzhou National Laboratory is a new research institution in the field of respiratory system diseases and prevention, and is a core technology force in the field of respiratory system diseases. Guangzhou Medical

Gelonghui FinanceOct 16, 2024 17:47